Podcast
Dr Javed Butler: Vericiguat & Mortality
Dr. Javed Butler addresses the ongoing debate about whether vericiguat provides cardiovascular mortality benefits for heart failure patients. He explains how historical clinical trial designs evolved to include both mortality and hospitalization endpoints, allowing for shorter follow-ups. However, in the Victoria trial, the severely ill patient population and limited 10.8-month average follow-up restricted definitive conclusions on mortality outcomes. Dr. Butler discusses promising directional trends and specific patient subgroups showing potential benefits while acknowledging the need for further long-term trials.
